Previous Article | Next Article 
Journal of Virology, May 2001, p. 4247-4257, Vol. 75, No. 9
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.9.4247-4257.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Hepatitis B Virus HBx Protein Activation of Cyclin
A-Cyclin-Dependent Kinase 2 Complexes and G1 Transit
via a Src Kinase Pathway
Michael
Bouchard,1
Stavros
Giannakopoulos,1
Edith H.
Wang,2
Naoko
Tanese,1 and
Robert J.
Schneider1,*
Department of Microbiology, NYU School of
Medicine, New York, New York 10016,1 and
Department of Pharmacology, University of Washington, Seattle,
Washington 981952
Received 29 November 2000/Accepted 5 February 2001
 |
ABSTRACT |
Numerous studies have demonstrated that the hepatitis B virus
HBx protein stimulates signal transduction pathways and may bind to
certain transcription factors, particularly the cyclic AMP response
element binding protein, CREB. HBx has also been shown to promote
early cell cycle progression, possibly by functionally replacing the TATA-binding protein-associated factor 250 (TAFII250), a transcriptional coactivator, and/or by
stimulating cytoplasmic signal transduction pathways. To understand the
basis for early cell cycle progression mediated by HBx, we
characterized the molecular mechanism by which HBx promotes
deregulation of the G0 and G1 cell cycle
checkpoints in growth-arrested cells. We demonstrate that
TAFII250 is absolutely required for HBx activation of
the cyclin A promoter and for promotion of early cell cycle transit from G0 through G1. Thus, HBx does not
functionally replace TAFII250 for transcriptional activity
or for cell cycle progression, in contrast to a previous report.
Instead, HBx is shown to activate the cyclin A promoter, induce
cyclin A-cyclin-dependent kinase 2 complexes, and promote cycling
of growth-arrested cells into G1 through a pathway
involving activation of Src tyrosine kinases. HBx stimulation
of Src kinases and cyclin gene expression was found to force
growth-arrested cells to transit through G1 but to stall at
the junction with S phase, which may be important for viral replication.
 |
INTRODUCTION |
Chronic infection with hepatitis B
virus (HBV) is closely associated with the development of
hepatocellular carcinoma in humans. Consequently, there has been
intense interest in HBV gene products that can alter cellular gene
activity. The smallest open reading frame of the mammalian HBVs,
including the human virus, encodes a 17-kDa regulatory protein known as
HBx (or X protein) (reviewed in references 2 and 92).
HBx is essential for productive infection by the mammalian HBVs
(12, 95). Studies initially characterized HBx as a
transcriptional transactivator of weak to moderate strength.
Transcription factors activated by HBx include NF-
B, NF-AT,
AP-1, and ATF/CREB (4, 6, 8, 45, 48, 51, 52, 55, 68, 73, 77, 81,
82, 90). In addition to stimulation of RNA polymerase
II-directed transcription, HBx also stimulates transcription by RNA
polymerases I and III (3, 43, 86, 88). HBx is
therefore a modest activator of many types of transcription elements
and factors (28, 29, 46, 51, 54, 60, 61, 90). Many of the
reported activities of HBx have been shown to result from its
ability to activate cytoplasmic signal transduction pathways,
particularly the Ras-Raf-mitogen-activated protein kinase (MAPK)
pathway (6, 18, 55, 86), the cell stress-induced
MEKK1-p38-c-Jun N-terminal kinase (JNK) pathway (8, 73),
and the family of Src tyrosine kinases (41). HBx activation of Src may be important for viral replication
(40). In vitro, HBx can interact with several
components of the transcriptional apparatus, including factors
TATA-binding protein (TBP), TFIIB, TFIIH, and the RPB5 subunit of RNA
polymerases (14, 60, 61). HBx also possesses nuclear
transcription-activating functions (23) that may involve
interaction with CREB (51, 59, 77, 90) or possibly a
reported coactivator activity (29, 30, 83).
HBx has been shown to stimulate deregulation of early cell cycle
checkpoint controls (7, 42, 71). Expression of HBx in
cells that have had their growth arrested by serum withdrawal results
in their transit through the G1 phase of the cell cycle but
without progression into S phase (71). Thus, in the
absence of serum, HBx-expressing cells are stalled at the
G1-S phase junction, whereas control cells without HBx
remain in G0. If serum is provided to growth-arrested cells
that express HBx, these cells advance more rapidly through
G1 and may enter S phase, in contrast to cells without
HBx, particularly if the cell is transformed (7, 42).
Although HBx activation of Ras has been shown to be necessary for
deregulation of the G0 checkpoint (7), there
is little understanding of the mechanism by which HBx promotes
early cell cycle progression. In this regard, HBx was also reported
to functionally replace TBP-associated factor 250 (TAFII250) in transcriptional activation, induction of cell
cycle progression, and inhibition of apoptosis in
ts13 cells. Thus, these data implicate both cytoplasmic signal transduction and nuclear transcription functions in the ability
of HBx protein to promote cell cycle progression. ts13 cells are from a hamster cell line containing a
temperature-sensitive defect in TAFII250 caused by a
single amino acid change in the TAFII250 protein
sequence (31, 76). The TAFII250
ts13 mutation causes cell cycle arrest and apoptosis
when these cells are shifted from the permissive temperature (33°C)
to the nonpermissive temperature (39.5°C).
TAFII250, the largest TAF identified, interacts
with TBP and several other TAFs (reviewed in references 1,
11, and 58), and it is essential for assembly of the TFIID
complex (89). It was recently established that
TAFII250 targets specific chromatin-bound promoters via
multiply acetylated histone H4 proteins. By utilizing its intrinsic
histone acetyltransferase (HAT) activity, TAFII250
activates transcription through chromatin remodeling and recruitment of
the transcription complex (36). TAFII250 is essential for activation of A- and D-type cyclin genes, a necessary event for progression through the cell cycle (67).
Importantly, extensive analyses of ts13 cells have
demonstrated that it is the HAT activity of TAFII250,
and not other activities, that is impaired at the restrictive
temperature (24). Thus, at the restrictive temperature,
failure of TAFII250 to induce cyclin A and D genes results in cell cycle arrest and ultimately apoptosis
(67), which results from the loss of
TAFII250 HAT activity. In addition, the effect of the
TAFII250 mutation in ts13 cells on cellular transcription is not global, and only a small number of genes are
affected (47, 67, 84). Transcription of the
c-fos gene, for example, is not influenced by a shift of
ts13 cells to 39.5°C, whereas the activity of the cyclin A
promoter is decreased by 8- to 10-fold.
The simian virus 40 large T antigen (SV40 T-Ag) and the human
cytomegalovirus (HCMV) major immediate-early proteins (MIEPs) can
overcome the transcriptional defect of ts13 cells at the
restrictive temperature for TAFII250 (19,
49). Rescue of ts13 cell transcription is partially
restored by the IEP86 protein, although near-complete rescue requires
expression from the entire major immediate-early transcription unit,
implying that at least several proteins are required to overcome the
loss of TAFII250 (49, 50). Moreover, studies demonstrate that while SV40 T-Ag and HCMV MIEPs can compensate for some of the functions of TAFII250, it is unlikely
that a single viral protein is able to replace the multiple functions
of TAFII250. For instance, the HCMV MIEPs cannot rescue
the cell cycle defect in ts13 cells grown at the
nonpermissive temperature for TAFII250 function,
although their expression does prevent apoptosis
(50). Genetic evidence also indicates that different MIEP
functions prevent apoptosis and stimulate transcription
(50). This is consistent with the multiple activities of
TAFII250, such as transcriptional activation, cell
cycle progression, and effects on apoptosis, involving distinct
and separable functions of TAFII250. Thus, the
multifunctional nature of TAFII250 could explain why
transcriptional activation of cyclin promoters by a rescuing protein
does not necessarily result in cell cycle progression or inhibition of apoptosis when ts13 cells are shifted to the
nonpermissive temperature. HBx protein was reported to promote cell
cycling in ts13 cells incubated at the restrictive
temperature for endogenous mutant TAFII250, as well as
to overcome the transcriptional defect (27). As HBx
has been shown to be an inducer of apoptosis in many cells (9, 16, 39, 66, 70, 74, 78, 79), it is unclear how
expression of HBx in a TAFII250 mutant cell line
can block the antiapoptotic effect that results from the loss of
TAFII250 activity.
Studies have characterized the temperature-responsive component of the
cyclin A promoter, demonstrating that this element contains an ATF/CREB
transcription factor binding site which is involved in its activation
(85). ATF and CREB factors and the ATF-CREB-responsive
element (CRE) site in cyclin A and D promoters can be induced via a Src
kinase signaling pathway (44). HBx can activate Src
kinases (40, 41), implicating an established mechanism of
action in HBx induction of cyclin gene activity. Moreover, HBx
is widely reported to bind to and activate ATF/CREB (reviewed in
reference 2). Thus, there are potentially multiple mechanisms by which HBx promotes early cell cycling. In this
report, we characterized the mechanism by which HBx promotes
cycling of growth-arrested cells. We examined whether HBx induction
of cell cycling occurs through its nuclear functions by replacing
TAFII250 or through its cytoplasmic functions by
activating Src kinases. We show that the induction of the cyclin A
promoter by HBx in ts13 cells, which is essential for
cell transit through G1, is dependent on activation of the
Src family of tyrosine kinases. HBx could not functionally replace
the loss of TAFII250 activity for activation of the
cyclin A promoter or for early cell cycle progression. Furthermore,
HBx induction of the cyclin A promoter through cytoplasmic
activation of Src kinases is shown to be involved in the release of
cells from quiescence and their transit through G1 to the
junction with S phase. HBx is shown to be located predominately in
the cytoplasm of ts13 cells regardless of temperature,
consistent with an absolute requirement for induction of cytoplasmic
signaling cascades but inconsistent with an essential requirement for
nuclear transcription functions. In fact, an HBx protein that was
engineered to concentrate in the nucleus by fusion to a nuclear
localization signal (NLS) failed to substitute for
TAFII250 function or to promote cell cycle progression.
Finally, HBx is shown to activate the endogenous cyclin A promoter
and cyclin A-cyclin-dependent kinase 2 (cdk2) complexes in wild-type
(TAFII250 containing) cells through cytoplasmic
activation of Src signaling pathways.
 |
MATERIALS AND METHODS |
Cell culture.
ts13 cells were maintained at
33°C in 5% CO2 in Dulbecco's modified Eagle's medium
(DMEM) containing penicillin (100 U/ml) and streptomycin (100 µg/ml),
supplemented with 10% fetal bovine serum. Chang cells were maintained
in DMEM at 37°C as described above.
Plasmids and viruses.
The HBx-expressing
plasmids, pAd-CMVX, pAd-HBxFlag, pAd-HBxo,
pAd-HBxNLSFlag, and pAd-HBxSLNFlag, the
TAFII250-expressing plasmid, the Csk-expressing
plasmid (pCaCsk), and the cyclin A promoter-driven luciferase reporter
plasmid (pCyA-Luc) have been described previously (23, 41,
84). High-concentration stocks of plasmids were purified using
the Concert High Purity Plasmid Maxiprep System (Life Technologies)
according to the manufacturer's instructions. Replication-defective
recombinant adenovirus (Ad) vectors have been described previously
(23). Ad-HBx and Ad-HBxo express wild-type HBx
and an HBx mutant mRNA that lacks all potential translation
initiation codons and does not synthesize HBx protein, respectively. HBx was inserted in place of Ad region E1. Ad vectors were propagated and titers were determined on 293 cells, which complement the loss of the E1 transcription unit.
Transfection, luciferase assays, and survival curves.
All
transient transfections were performed by both standard calcium
phosphate transfection methods and lipid methods using Lipofectamine-Plus (Life Technologies) according to the manufacturer's instructions. Both methods gave similar results, and only those from
the Lipofectamine-Plus transfections are reported here. Luciferase reporter assays were performed using the Promega luciferase assay system according to the manufacturer's instructions. To analyze HBx-induced ts13 survival at the nonpermissive
temperature, cells were cotransfected with 0.5 µg of a green
fluorescent protein (GFP)-expressing plasmid (pGFP) and amounts of
pAd-CMV control vector or pAd-CMVX (23) ranging from 1 to
10 µg/5 × 106 cells. After 24 h of recovery to
ensure protein expression, cells were either maintained at 33°C
(permissive for TAFII250) or shifted to 39.5°C
(restrictive). At indicated times after the temperature shift, relative
cell survival was calculated from the mean of surviving GFP-expressing
cells, collected by viewing 10 fields at 40× power using a standard UV
light microscope outfitted with GFP filters.
Flow cytometry.
These studies were carried out as previously
described (7), with minor changes as described below.
Briefly, Chang cells were made quiescent by cultivation in DMEM without
serum for 30 h, infected with replication-defective Ad vectors
expressing HBx (Ad-CMVX) or a mutant devoid of all potential
HBx AUG codons, known as HBxo (Ad-CMVXo), at 25 PFU per cell,
and maintained in DMEM in the absence of serum for up to 24 h.
Cells were lysed in a solution containing 0.1% Nonidet P-40, 50 µg
of propidium iodide per ml, 100 µg of DNase-free RNase A per ml, 5 mM
NaCl, and 10 mM trisodium citrate. Flow cytometry was performed without modification as described previously (34). Results shown
are typical of three independent trials.
Kinase assays.
For the cyclin A-cdk2 complex assay,
serum-starved Chang cells were transfected with plasmid DNAs for
24 h and lysed, and extracts were prepared as described previously
(7). Cyclin A was specifically immunoprecipitated with a
commercial monoclonal antibody to cyclin A (Upstate Biotechnology, Lake
Placid, N.Y.), and equal fractions were resolved by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (12% gel) and
immunoblotted with the same antibody, followed by visualization with
the enhanced chemiluminescence system (ECL; Amersham). The remaining
immunoprecipitate was added to in vitro kinase reactions containing 5 µCi (1 Ci = 37 GBq) of [
-32P]ATP and 50 mg of
histone H1 per ml in 50-µl reaction volumes as described previously
(7, 33). Proteins were resolved by SDS-PAGE (12% gel) and
quantitated and detected by phosphorimage analysis. Data represent
typical results from three independent experiments. The Src kinase
assay was carried out as described previously (41), with
minor changes. Briefly, cells were lysed in buffer containing 1%
Nonidet P-40, 150 mM NaCl, 20 mM Tris-HCl (pH 8), 2.5 mM EDTA, 1 mM
Na3VO4, 50 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 10 µg of aprotinin per ml, and 10 µg of leupeptin per ml.
c-Src was immunoprecipitated from equal amounts of extract using a
commercial monoclonal antibody (Upstate Biotechnology), and equal
amounts were resolved by SDS-PAGE (12% gel) and immunoblotted with the
same antibody. Equal fractions of the remaining immunoprecipitate were
resuspended in kinase buffer (20 mM HEPES [pH 7.4], 10 mM MnCl2) with 0.2 µg of acid-denatured enolase (Sigma), 20 µCi of [
-32P]ATP, and 10 µM ATP, as previously
described (41). Samples were resolved by SDS-PAGE (12%
gel) and subjected to phosphorimage analysis. Data shown are typical of
three independent experiments.
Indirect immunofluorescence.
Immunofluorescent antibody
staining of ts13 cells transfected with HBx
(pAd-HBxFlag) was performed as previously described (23). Briefly, cells were grown on collagen-coated
coverslips, transfected with either pAd-HBxFlag, pAd (DNA vector
control), pAd-HBxNLSFlag, or pAd HBx SLNFlag, and allowed to
recover for 24 h. For fixation and permeabilization, the medium
was removed and cells were washed twice with phosphate-buffered saline
(PBS) and then treated in 95% ethanol plus 5% acetic acid overnight at
20°C or in 70% acetone plus 30% methanol for 10 min at
20°C. Fixed and permeabilized cells were washed with PBS and then
blocked in PBS plus 1% nonfat dry milk for 30 min at 37.5°C. Cells
were incubated with anti-Flag M1 antibody (Kodak) for 1 h at
37°C, washed four times with PBS, and then incubated with secondary donkey anti-mouse fluorescein isothiocyanate (FITC)-conjugated antibody. Cells were visualized and photographed using a Zeiss Axiophot fluorescence photomicroscope. Both fixation
methods gave identical results.
 |
RESULTS |
HBx requires TAFII250 activity for cyclin A
promoter transcription.
Studies first examined the ability of
HBx to stimulate transcription of a cyclin A promoter-luciferase
reporter construct in ts13 cells at the permissive
temperature for TAFII250 transcriptional activity
(33°C). Cells were transiently transfected with a plasmid expressing
wild-type HBx or control plasmid DNA and were maintained at the
permissive temperature. Cotransfection with pGFP demonstrated equal
transfection efficiencies in all samples (~70%; data not shown).
HBx was found to reproducibly induce the ectopic cyclin A promoter
two- to threefold at the permissive temperature (Fig. 1). These results are consistent in
magnitude with the widely reported weak to moderate transactivation
activity of HBx in a variety of cells and with different promoters
(typically two- to sixfold). To evaluate whether HBx can rescue the
ts13 transcription defect resulting from inactivation of
TAFII250 at the restrictive temperature, cells were
transfected for 5 h at 33°C with expression plasmids for HBx
and the cyclin A promoter-controlled luciferase reporter and were
maintained at the nonrestrictive temperature (33°C) or shifted to
39.5°C. At the restrictive temperature for TAFII250
activity, HBx only marginally stimulated transcription of the
transfected cyclin A promoter just slightly above that of vector alone
(Fig. 1). Importantly, HBx did not even stimulate the cyclin A
promoter to the basal levels of transcription that were observed at the
permissive temperature. In fact, the experiment could not be continued
past 30 h of transfection due to cell death, indicating the
failure of HBx to rescue TAFII250 function.
Transfection of cells with the HBx expression plasmid, ranging from
0.25 to 10 µg per 107 cells (a 40-fold concentration
range), also failed to recover cyclin A promoter activity at the
restrictive temperature (data not shown). Identical results were
obtained when cells were transfected at 33°C and then shifted to
39.5°C 1 day later or when they were transfected at 39.5°C and
maintained at the nonpermissive temperature. Consequently, there were
no experimental conditions in which HBx replaced
TAFII250 function for cyclin A promoter activity. In contrast, cotransfection of ts13 cells at the restrictive
temperature (39.5°C) with the cyclin A promoter-reporter construct
and a wild-type TAFII250 expression vector recovered
almost full cyclin A promoter transcriptional activity compared to
control cells expressing functional endogenous TAFII250
at the permissive temperature. Since about 70% of the cells were
transfected (data not shown), these data demonstrate that ectopic
expression of TAFII250 can rescue the transcription
defect of ts13 cells within 24 h at 39.5°C. Ectopic
expression of wild-type TAFII250 in ts13
cells at the permissive temperature actually reduced cyclin A promoter
activity slightly, possibly as a result of squelching due to
supraphysiological expression levels. HBx did not lose function at
39.5°C, since at 39.5 and 33°C it stimulated transcription equally
well of a reporter controlled by a minimal promoter and four AP-1
transcription factor binding sites in Chang cells (Table
1). In addition, HBx is stably
synthesized at 39.5°C (shown later in Fig. 2). Collectively, these
data demonstrate that HBx requires TAFII250
activity for cyclin A promoter activation, suggesting that nuclear
HBx functions are either insufficient or unnecessary to promote
early cell cycling, which was investigated next.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 1.
HBx stimulation of cyclin A promoter requires
TAFII250 function. ts13 cells grown at
33°C were transiently transfected with control vector, HBx
expression vector, or wild-type TAFII250
expression vector plus a cyclin A promoter-luciferase reporter
construct. Cells were maintained at the permissive temperature
(33°C) or shifted 5 h later to the nonpermissive temperature
(39.5°C) for TAFII250 activity as described
previously (24). At 24 h posttransfection,
transcriptional activity was measured by relative luciferase light
units and normalized for transfection efficiency and protein
concentration. Data represent the means of at least three independent
experiments, with calculated standard errors shown.
|
|
HBx protein engineered to concentrate in the nucleus requires
TAFII250 function.
Most studies have found HBx
protein to be largely, but not exclusively, in the cytoplasm of a
variety of cell types, whether expressed by transient transfection or
in the context of viral infection (e.g., see references 20, 21,
and 23). The cellular location of HBx in ts13
cells was investigated first using an HBx construct containing a
C-terminal foreign Flag epitope. HBxFlag was shown previously to
behave identically to unmodified wild-type HBx (23).
ts13 cells were transfected with the HBxFlag expression plasmid or control vector DNA, and then indirect immunofluorescence analysis was carried out on cells fixed to coverslips and stained with
anti-Flag antibodies followed by FITC-conjugated secondary antibodies.
Although there was a low level of nuclear staining, the majority of
HBx was found in the cytoplasm in all cells observed (Fig.
2). Furthermore, there was no change in
wild-type HBx intracellular distribution when ts13 cells
were shifted to the nonpermissive temperature for
TAFII250 activity 24 h prior to fixation (Fig. 2).
An HBx variant engineered to contain an N-terminal NLS from SV40
T-Ag (HBxNLS) (23) was concentrated in the nucleus but retained some cytoplasmic distribution. An HBx control which
contains a defective NLS sequence (HBxSLN) (23)
remained cytoplasmic. HBxNLS and HBxSLN have been
characterized extensively in a variety of cell types (e.g., see
references 23 and 77). Shifting of the cells to 39.5°C
did not alter the intracellular distribution of HBxNLS or
HBxSLN proteins from that observed at 33°C (data not
shown). It can be concluded, therefore, that HBx proteins are
synthesized and retain their typical intracellular distribution at both
33 and 39.5°C.

View larger version (72K):
[in this window]
[in a new window]
|
FIG. 2.
HBx remains predominantly cytoplasmic in
ts13 cells regardless of temperature. ts13 cells
were grown on coverslips at 33°C, transiently transfected with a
plasmid expressing HBxFlag, which is an HBx protein containing
a C-terminal Flag epitope that behaves identically to wild-type
HBx, or HBxFlag containing an NLS (HBxNLS) or a control
plasmid expressing a mutant NLS (HBxSLN) (23). Cells
were maintained at 33°C or shifted to 39.5°C for 24 h, fixed and
permeabilized on coverslips, and reacted with M2 anti-Flag antibodies
followed by FITC-conjugated secondary antibody to visualize
HBxFlag. Immunofluorescence photomicrographs (magnification, ×400)
are shown for cells representative of each field. Control cells with
vector alone did not demonstrate antibody staining (23,
74; data not shown).
|
|
Studies were then conducted to examine whether HBx failed to
functionally replace TAF
II250 at 39.5°C because too
little HBx
accumulates in the nucleus in
ts13
cells. Cells at the permissive
or restrictive temperature were
transfected with wild-type HBx,
HBxNLS, or wild-type
TAF
II250 expression plasmids, and the effect
on cyclin
A promoter activity was determined (Fig.
3A). At the
restrictive temperature,
ectopic expression of wild-type TAF
II250
recovered
normal levels of cyclin A promoter transcriptional activity
compared to
the nonrestrictive temperature. There was no recovery
of cyclin A
promoter activity at the restrictive temperature by
HBx or
HBxNLS proteins. Thus, nuclear HBx protein does not
functionally
replace TAF
II250 transcriptional activity
at the restrictive temperature.
Studies performed at the nonrestrictive
temperature for TAF
II250
activity demonstrate similar
activation by HBxNLS and HBx. Since
some HBxNLS remains
cytoplasmic whereas the nuclear level of HBx
is increased strongly,
these results indicate that even with increased
levels of HBx in
the nucleus, like wild-type HBx, TAF
II250 function
is still required for activation of the cyclin A promoter. Because
titration analysis of HBx showed that even 10-fold-lower levels
could activate transcription, we suspect that the small amount
of
cytoplasmic HBxNLS in
ts13 cells is sufficient for
activation
of the cyclin A promoter. These results also suggest that
nuclear
and cytoplasmic HBx functions are involved in early cell
cycle
progression, but the nuclear function does not include a
previously
reported TAF
II250 activity which could not
be reproduced here.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 3.
Nuclear HBx does not complement for loss of
TAFII250 in cyclin A or CRE-dependent promoter
activity. (A) ts13 cells were transiently transfected with a
cyclin A promoter-luciferase reporter construct and a vector expressing
wild-type HBx, an HBx engineered to concentrate largely but not
completely in the nucleus by inclusion of the SV40 T-Ag NLS
(HBxNLS) (23), or wild-type TAFII250.
(B) Cells were transfected as described above but with a 4×
multimerized CRE-basal promoter-luciferase reporter construct. Cells
were maintained at 33°C or shifted to the nonpermissive temperature
for TAFII250 (39.5°C) for 24 h, and
transcriptional activity was determined as described in the legend for
Fig. 1. Results represent the means of at least three independent
experiments, with calculated standard errors shown.
|
|
Studies were therefore performed to determine whether the nuclear
HBx function involves activation of the transcription factor
CREB,
since HBx has been shown to bind and activate CREB in vitro
and
since CREB activation is required for stimulation of the cyclin
A
promoter. Cotransfection of
ts13 cells at the permissive
temperature
with a CRE-luciferase reporter and wild-type HBx (Fig.
3B) demonstrated
two- to threefold activation of CREB-dependent
transcription by
wild-type HBx. Similar analysis using HBxNLS,
which is largely
but not entirely distributed in the nucleus,
demonstrated slightly
lower activation of the CREB-dependent reporter.
This is consistent
with a previous report which suggested that HBx
activation of
CREB might involve both cytoplasmic and nuclear
HBx functions
(
90). At the restrictive
temperature for TAF
II250, neither wild-type
HBx nor HBxNLS proteins stimulated CREB-dependent
transcription
(Fig.
3B). This is consistent with an essential
requirement for
TAF
II250 function in transcriptional
activation by HBx. Studies
presented later demonstrate that HBx
activation of Src kinase
signaling is involved in CREB activation as
well.
HBx requires TAFII250 activity and cytoplasmic
functions to promote cell viability and cycling.
We sought to
determine whether HBx promotion of ts13 cell viability
and cycling involves nuclear HBx functions that require or are
independent of TAFII250 activity. Cells were
cotransfected with a GFP expression vector and pAd-CMVX or control
plasmid DNA and then maintained at the permissive temperature (33°C)
or shifted to a restrictive temperature (39.5°C) for endogenous
TAFII250 activity. Under these conditions, all
GFP-expressing cells were cotransfected with either
TAFII250, HBx, or vector DNA at ~70% efficiency,
regardless of temperature (data not shown). At different times
following the temperature shift, cells were observed by light
microscopy, and the number of viable GFP-expressing cells was
quantified as described in Material and Methods. Approximately 90% of
the transfected ts13 cells containing wild-type
TAFII250 and GFP survived at the nonpermissive
temperature, indicating inhibition of cell death (Fig.
4). Cells expressing HBx were
identical to control cells transfected with vector alone at the
nonpermissive temperature, demonstrating widespread cell death. Thus,
HBx did not delay the onset or rate of cell death and therefore did
not promote cell cycling in the absence of TAFII250
activity. Identical results were obtained with HBxNLS, which
concentrates in the nucleus (data not shown). We attempted to isolate
surviving colonies of ts13 cells that were transformed by
HBx at 39.5°C. Cells were transformed with vector alone or
plasmids expressing HBx, HBxNLS, or wild-type
TAFII250, at concentrations ranging from 1 to 10 µg
of plasmid per 5 × 106 cells. The numbers of surviving
transformants after 2 weeks of selection at 39.5°C are shown in Table
2. HBx, HBxNLS, and vector DNA
all gave rise to fewer than two colonies per 107 cells, a
transformation frequency of 2 × 10
7. In comparison,
cells transformed with TAFII250 averaged 7 × 106 transformants per 107 cells, a
transformation efficiency almost equal to the efficiency of
transfection, indicating that the majority of cells transfected with
TAFII250 could be rescued. In addition, attempts to
produce stably selected ts13 cells expressing HBx under
a regulated promoter failed due to cell death, likely resulting from
leaky synthesis of HBx protein (data not shown). Collectively,
these results demonstrate that nuclear HBx functions are not
sufficient to promote cell viability and cycling in the absence of
TAFII250 activity.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 4.
Effect of HBx on ts13 cell viability and
growth in the absence of TAFII250 activity.
ts13 cells at 33°C were transiently
transfected with vector alone or with an HBx or
wild-type TAFII250 expression vector. Duplicate plates
of cells containing either vector alone or HBx were maintained at
the permissive (33°C) temperature for endogenous
TAFII250 activity. Cell viability and growth were
determined at days 1 to 4 after the shift to the nonpermissive
temperature based on cotransfected cells expressing a GFP marker, as
described in Materials and Methods. Analysis of cell viability
commenced at 24 h following the shift of samples to the
nonpermissive temperature. Data represent a typical experiment that did
not differ from three other studies by more than 10% and are displayed
as the mean numbers of surviving cells per field obtained by the
average of 10 fields per time point. An equal number of cells per field
was plated at the start of the experiment.
|
|
HBx stimulates the cyclin A promoter, promotes formation of
cyclin A-cdk2 complexes, and deregulates early cell cycle checkpoints
in a Src kinase-dependent manner.
It was shown previously that
activation of transcription by HBx in part involves its cytoplasmic
stimulation of Src kinase signaling and the Ras-Raf-MAPK/JNK pathway
(6, 8, 40, 41, 73, 86). Moreover, HBx was shown
previously to stimulate cyclin E and A synthesis by acting on
cytoplasmic signal transduction pathways (7). The failure
of HBx to stimulate cell cycling and the cyclin A promoter in the
absence of TAFII250 activity at 39.5°C, even when
relocated to the nucleus (Fig. 1 and 3), implicated HBx activation
of signaling pathways in this action. We therefore characterized
HBx activation of the endogenous cyclin A promoter and cyclin
A-cdk2 complexes. Previous studies have shown that HBx can
deregulate the G0 cell cycle control checkpoint in a
variety of cell types with arrested growth and can facilitate transit
into or through G1 to the early S phase transition
(7, 42, 71). We first show that HBx promotes transit
of G0-G1-arrested cells through G1
to the G1-S junction in the absence of serum. It was not
possible to conduct these studies in ts13 cells, which apoptose when growth is arrested by serum depletion (67),
particularly with expression of HBx (data not shown). Consequently,
Chang cells, a human liver cell line which can have its growth arrested
by serum withdrawal without inducing apoptosis, were used.
Quiescent cells (cells in G
0 and at the
G
0-G
1 junction) were accumulated by serum
withdrawal. Cells were then transduced by
a replication-defective Ad
vector lacking the Ad E1 region, which
in its place expresses the
HBx gene, or by a control HBxo gene
which expresses an mRNA
that cannot synthesize HBx protein (
7,
23,
40,
73).
Studies have shown that these vectors remain
genetically silent for the
time course of these experiments (
73).
Cells were lysed at
various times after transduction with Ad vectors,
and flow cytometry
was performed on propidium iodide-treated nuclei
(Fig.
5). In the absence of
serum stimulation, cells expressing
the
HBxo gene did not exit from the G
0-G
1
fraction upon the termination
of these studies (24 h posttransfection).
Control cells expressing
HBxo in the presence of serum proliferated
more rapidly and entered
S phase during this same time course. In
comparison, HBx-expressing
cells in the absence of serum showed
a gradual increase in accumulation
at the G
1 junction with
early S phase which was striking by 24
h of expression. Although
cells expressing HBx in the absence
of serum did not enter S phase
and replicate, there was an evident
increase in cell number at the
rightward G
1 transition with S
phase. This likely
represents the initiation of DNA decompaction
in the nucleus which
precedes entry into S phase and causes an
increased fluorescent signal
(
62). The disappearance of the
small fraction of cells in
the G
2-M phase in the HBx-expressing
sample at time
zero probably represents cells that cycled through
to G
1
phase and then stopped (
71).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 5.
Effect of HBx on the cell cycle. Change cells were
accumulated largely in the G0-G1 phase by
30 h of maintenance in serum-free medium and then transduced with
replication-defective Ad vectors with the wild-type HBx or mutant
HBxo gene substituted for region E1. HBxo is a control that
cannot synthesize HBx protein. Control cells containing HBxo
were supplemented with 10% serum at the time of Ad transduction. Flow
cytometry was performed using propidium iodide staining of nuclei.
Histograms of nuclei are shown, obtained from cells at time zero
(immediately following Ad transduction) and at 16 and 24 h. The
DNA content of the nuclei was determined within 2 h of cell lysis
by flow cytometry using the MODFIT program. Data are presented from a
single experiment which did not vary by more than 10% in three
trials.
|
|
Studies next determined whether HBx activation of Src kinases is
important for deregulation of early cell cycle checkpoints.
Chang cells
were transfected with a plasmid expressing the kinase
Csk, which
phosphorylates and downregulates Src kinases. Csk was
chosen for these
studies because it very specifically blocks the
family of Src kinases.
At 8 h following transfection, cells were
transduced with an Ad
vector expressing HBx or HBxo. Approximately
70% of the cells
were found to be transfected, whereas 95% were
transduced by the Ad
vector (data not shown). Previous studies
demonstrated that Csk does
not inhibit the expression of HBx controlled
by the CMV promoter
(
40,
41). Expression of Csk in HBx-expressing
cells reduced the fraction of cells that accumulated at the
G
1-S
phase junction by about half at 24 h in the
absence of serum.
Various chemical inhibitors of Src kinases were found
to provide
equivalent results and will be published elsewhere. Cells
expressing
both Csk and HBxo were identical to the HBxo
controls in the absence
of serum (data not shown). Since Src kinases
are stimulated by
HBx acting in the cytoplasm (
41),
which is required for HBx
promotion of cell cycling as shown here,
we did not evaluate the
effect of HBxNLS. These results demonstrate
that HBx deregulates
early cell cycle checkpoints in a Src
kinase-dependent manner,
an event that includes synthesis of cyclin A
and activation of
cyclin A-cdk2
complexes.
Studies therefore examined the role of cytoplasmic HBx activities
in deregulation of early cell cycle control. Since many
cytoplasmic
functions of HBx can be accounted for by its activation
of Src
signaling, the role of Src activation in the stimulation
of the
endogenous cyclin A promoter was investigated. Serum-starved
Chang
cells were transfected with HBx or HBxo expression vectors,
with or without cotransfection of a plasmid expressing the kinase
Csk.
Cell extracts were prepared 30 h later, c-Src was specifically
immunoprecipitated, and HBx activation was shown by the ability
of
immunoprecipitated Src to phosphorylate the substrate enolase
in vitro
(Fig.
6A). HBx induced a fourfold
activation of Src compared
to cells transfected with the HBxo
vector which was prevented
by coexpression with Csk (Fig.
6A). Equal
amounts of Src were
assayed, as shown by the immunoblot analysis of the
immunoprecipitates.
Studies then determined whether HBx stimulates
endogenous cyclin
A gene expression through a Src kinase pathway in
growth-arrested
Chang cells. Cells were assayed for cyclin A protein
levels and
cyclin A-cdk2 activity 24 h after transfection,
corresponding
to the accumulation of cells in G
1-early S
phase (Fig.
5). Compared
to the HBxo control, HBx induced about
a fivefold increase in
cyclin A protein levels in these cells, which
was blocked by coexpression
of Csk (Fig.
6B). The activity of cyclin
A-cdk2 complexes was
determined by immunoprecipitation of cyclin A
followed by an in
vitro assay of cdk2 phosphorylation of the substrate
histone H1
(
7) (Fig.
6B). Compared to the HBxo
control, HBx induced a
fivefold stimulation of cyclin A-cdk2
complexes in serum-starved
cells by 24 h after transfection, which
was prevented by coexpression
with Csk. These data therefore
demonstrate that HBx stimulation
of Src kinases is an important
cytoplasmic component of deregulation
of early cell cycle control.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 6.
HBx stimulates endogenous cyclin A promoter and
cyclin A-cdk2 complexes through a Src kinase pathway. Quiescent
serum-starved Chang cells were transiently transfected at ~70%
efficiency (data not shown) with vectors expressing HBx or
HBxo, with and without cotransfection of a plasmid expressing Csk,
a negative regulator of Src kinases. At 24 h posttransfection, cell
lysates were prepared. (A) pp60 c-Src was immunoprecipitated from equal
amounts of cell lysates using a specific monoclonal antibody, and equal
fractions were resolved by SDS-PAGE (12% gel) and immunoblotted with
the same antibody (Src blot) or assayed for in vitro phosphorylation
activity with [ -32P]ATP and the substrate enolase (Src
activity). (B) Cyclin A was immunoprecipitated using a specific
monoclonal antibody from equal amounts of lysate, and equal fractions
of the immunoprecipitate were resolved by SDS-PAGE (15% gel) and
immunoblotted for cyclin A protein (cyclin A blot) or assayed for
associated cdk2 activity by in vitro phosphorylation of histone H1, a
substrate of cdk2, using [ -32P]ATP. Phosphorylated
enolase and histone H1 were resolved by SDS-PAGE (12% gel),
autoradiographed, and quantitated by digital densitometry. Results
shown are typical of three independent experiments which did not vary
by more than 20%.
|
|
Studies next showed that HBx activation of Src signaling is
also vital for stimulation of the ectopic cyclin A promoter-reporter
in
ts13 cells. Cells were cotransfected with vectors expressing
HBx or TAF
II250, plus the cyclin A
promoter-reporter, with or
without cotransfection of a plasmid
expressing Csk. Cells maintained
at the permissive temperature for the
ts13 mutation in TAF
II250
showed a
consistent increase in cyclin A promoter activity of
two- to threefold
with HBx expression, which was blocked by overexpression
of Csk
(Fig.
7). At the restrictive temperature
for TAF
II250,
HBx stimulated the cyclin A promoter
only very slightly, and this
stimulation was also blocked by Csk
expression. As a control,
cells maintained at the restrictive
temperature and expressing
wild-type TAF
II250 were
shown to be unaffected by overexpression
of Csk. Furthermore, Csk did
not downregulate transcription of
a CMV promoter-controlled
reporter construct (data not shown),
excluding inhibition of
HBx activity by a general decrease in
transcription (Fig.
7). Thus,
HBx stimulates the cyclin A promoter
and deregulates early cell
cycle control through a pathway that
requires TAF
II250
function and activation of Src kinases.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 7.
HBx stimulation of cyclin A promoter through a Src
kinase pathway. ts13 cells grown at the permissive
temperature (33°C) or the restrictive temperature (39.5°C) were
transiently transfected with the cyclin A promoter-luciferase
reporter construct and control vector, HBx, or wild-type
TAFII250, with or without a cotransfected Csk
expression vector. Cells were then maintained at 33°C or shifted to
39.5°C 5 h after transcription. In some studies, cells were
shifted to 39.5°C 24 h after transfection at 33°C, with
identical results (data not shown). At 24 h posttransfection,
transcriptional activity was measured by relative luciferase light
units and normalized for transfection efficiency and protein
concentration. Data represent the means of at least three
independent experiments, with calculated standard errors shown.
|
|
 |
DISCUSSION |
The HBV HBx protein possesses a wide variety of activities,
such as activation of cytoplasmic signal transduction pathways, induction or sensitization of cells to apoptosis, loss of early cell cycle control checkpoints, possibly direct interaction with several components of the transcription apparatus, and a weak to
moderate activation of transcription directed by RNA polymerases I, II,
and III. Given the variety of activities attributed to HBx and the
fact that its ability to activate transcription is at best moderate,
there has been considerable difficulty in firmly establishing the
mechanism(s) through which HBx activates transcription. The in
vitro demonstration of interactions between HBx and components of
the transcriptional machinery such as RBP5 or TFIIH or the transcription factor ATF/CREB has led to the suggestion that HBx functions directly in the nucleus (14, 51, 60, 61, 90). Transcriptional activation by HBx, according to this model, is a
consequence of direct interaction with any of several transcription factors in the nucleus. While most evidence points to a largely cytoplasmic location for HBx, some of the protein is typically in
the nucleus, providing support for this model (20, 21, 23, 63,
72). Moreover, HBx is thought to activate the transcription factor CREB, at least in part by direct interaction in the nucleus (90). Another large body of evidence also supports a
cytoplasmic function for HBx in transcriptional activation.
Activation of NF-
B, NF-AT, and AP-1 by HBx as well as
stimulation of transcription directed by RNA polymerases, I, II, and
III involve HBx activation of cytoplasmic signaling (6-8,
15, 17, 18, 23, 32, 38, 40, 41, 43, 48, 55, 73, 74, 86-88).
Furthermore, most studies on HBx cellular location have
demonstrated that most of the protein is located in the cytoplasm,
regardless of whether it is synthesized during transient transfection
or in the context of woodchuck hepatitis virus or human HBV infection
of liver cells in vivo (20, 21, 23, 35, 63, 72). This is
in accord with the observation that cytoplasmic HBx activation of
Src signaling, in particular, strongly stimulates viral replication in
cultured cells (40).
Ras and Src signal transduction pathways, both of which are activated
by HBx, are critical effectors for progression of cells to the
G1-early S phase transition of the cell cycle. Transit of
quiescent cells through G1 involves stimulated synthesis of cyclin D followed by cyclin E, both of which associate with and activate cdk-4, -6, and -2 (reviewed in reference 65).
Transit of cells to the S phase junction involves synthesis of cyclin A, which associates with and activates cdk2. Ras and Src signaling are
involved in multiple events for progression to the G1-S
transition (65), which include activation of Fos and Jun
(AP-1) and ATF/CREB family members (5, 10, 37, 44, 53, 56, 64,
91; reviewed in reference 80). Studies have
demonstrated that a key target of these signaling events for
G1 progression is activation of cyclin D and A promoters by
ATF/CREB transcription factors (69, 75, 85) in conjunction
with specific activation of TAFII250 (85).
The critical function of TAFII250 for activation of
cyclin D and A promoters was shown to be its intrinsic HAT activity, as
the ts13 cell mutation renders TAFII250 HAT
defective at the restrictive temperature, prevents D and A cyclin gene
transcription, and blocks progression to the G1-early S
transition (24).
In this study, we explored the functions of HBx in promoting early
cell cycling, including its purported functional replacement of
TAFII250 (27). Since
TAFII250 couples transcriptional activation to cell
proliferation, functional substitution by HBx would be unprecedented, given that it is only 17 kDa in size and possesses no
known enzymatic activities. It would also be expected to reflect a
novel and underscribed proto-oncogenic activity of HBx, because continuous expression of HBx is presumably required during virus replication (21). We showed that HBx does not
functionally replace known activities of TAFII250.
HBx did not stimulate the cyclin A promoter in the absence of
TAFII250 activity (Fig. 1), regardless of whether
the nuclear levels of HBx were elevated (Fig. 2 and 3), and it
did not rescue cells from death induced by the absence of
TAFII250 activity (Table 1; Fig. 4). However, it was
found that HBx required TAFII250 function to
stimulate the cyclin A promoter (Fig. 1, 6, and 7). HBx also
required TAFII250 function to induce quiescent cells to
transit from G1 to the S phase (Fig. 5 and 6), since
switching cells to the restrictive temperature for
TAFII250 blocked cell cycling. Since the only defect at
the restrictive temperature is in TAFII250 function and
since TAFII250 function is essential for cell cycle
progression (24, 49, 50, 67, 75, 84, 85), these data
demonstrate that HBx does not override the requirement for
TAFII250 in stimulating cell cycling. These data are
consistent with other previous reports demonstrating induction of early
cell cycling by HBx (and presumably activation of the cyclin D
promoter as well) (6, 7, 42, 71), possibly to the
G1-early S phase junction (71). In addition, HBx activation of Src signaling, which is coupled to activation of
Ras (41), was shown to be important for progression of
cells through G1 and activation of the cyclin A promoter
(Fig. 6 and 7).
The results reported here are consistent with critical cytoplasmic
functions of HBx in the stimulation of early cell cycling. HBx
stimulation of Src signaling was found to be essential and is
consistent with the established critical importance of Src and Ras in
promoting progression of cells through G1. The inability of
HBx to functionally replace TAFII250 during 24 to
30 h of expression is also consistent with the established
longevity of the TAFII250-TFIID complex. Most studies
demonstrate that this complex is very stable. In ts13 cells
at the restrictive temperature for TAFII250, almost 24 h was required for replacement of the mutant form of
TAFII250 by ectopically expressed wild-type protein
(19, 49). Thus, the reported rescue by HBx of
ts13 TAFII250 within 5 h of the inactivating temperature shift, if correct, would be unprecedented (27). However, HBx has been shown to bind in vitro to
the CREB transcription factor (4, 51, 77, 90) and to
stimulate CREB-dependent transcription in vivo (59, 90).
Furthermore, an ATF/CREB element can function in transcriptional
activation of cyclin D and A genes. Taken together, these observations
raised the possibility that perhaps HBx might circumvent
TAFII250 function by activating CREB, leading to cell
cycling and prevention of cell death. Nevertheless, neither wild-type
HBx nor a variant engineered to concentrate in the nucleus blocked
cell death or displayed any TAFII250-independent
activity, including transcriptional activation of the cyclin A promoter
and CREB-dependent transcription at the restrictive temperature for
TAFII250 (Fig. 3). Although nuclear HBx was not
sufficient to activate cell cycling, studies need to determine its
involvement in promotion of early cell cycling, possibly by direct
interaction between HBx and CREB.
HBx stimulation of the cyclin A promoter and G1 cell
cycle progression may represent a significant activity in the HBV life cycle. HBx expression during infection by HBV may stimulate
quiescent hepatocytes, not to divide but to transit the
G1-to-S-phase transition. A similar function is well
established for regulatory proteins of many oncogenic viruses. It is
thought that release of cells from quiescence may aid in viral
replication by expanding the pool of deoxynucleoside triphosphates
(dNTPs), which is significantly restricted during G0 and is
elevated during the G1 transition (22).
Moreover, dNTP pools are much lower in the cytoplasm, where HBV
replicates, than in the nucleus, which could present a considerable
impediment to HBV replication in quiescent cells. Transit through
G1 would therefore increase dNTP metabolism and elevate the available pool for HBV replication. In contrast, if HBx
were to function as a TAFII250-like protein, promoting
cells into cycling, this would be deleterious, as studies have shown greatly impaired HBV replication in cells during S phase
(57). Importantly, for classic retroviruses,
depletion of dNTP pools, particularly dCTP, has been shown to be
responsible for arrest of viral reverse transcription in G0
cells, which is relieved by transit into the G1-S
transition or by supplementation of G0-arrested cells with
high levels of dNTPs (13, 25, 26, 93, 94). HBx has
been shown to be required for HBV replication (12, 95), which also utilizes reverse transcription of the viral RNA genome. In
striking similarity to classic retroviruses, HBx promotes HBV reverse transcription and second-strand DNA synthesis in cultured cells
through a pathway that involves HBx activation of Src kinases (40). Thus, our data support a role for HBx
stimulation of early cell cycle transit, in part through Src
kinase and TAFII250 stimulation of cyclin promoters and
activation of cdks, so as to promote viral replication.
 |
ACKNOWLEDGMENTS |
This work was supported by NIH grants CA56533 (R.J.S.), CA74476
(M.B.), and GM51314 (N.T.) and by American Cancer Society grant
RPG-98-201-CCG (E.H.W.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology, NYU School of Medicine, 550 First Ave., New York, NY
10016. Phone: (212) 263-6006. Fax: (212) 263-8276. E-mail:
schner01{at}popmail.med.nyu.edu.
 |
REFERENCES |
| 1.
|
Albright, S. R., and R. Tjian.
2000.
TAFs revisited: more data reveal new twists and confirm old ideas.
Gene
242:1-13[CrossRef][Medline].
|
| 2.
|
Andrisani, O., and S. Barnabas.
1999.
The transcriptional function of the hepatitis B virus X protein and its role in hepatocarcinogenesis.
Int. J. Oncol.
15:1-7.
|
| 3.
|
Aufiero, B., and R. J. Schneider.
1990.
The hepatitis B virus X-gene product trans-activates both RNA polymerase II and III promoters.
EMBO J.
9:497-504[Medline].
|
| 4.
|
Barnabas, S.,
T. Hai, and O. M. Andrisani.
1997.
The hepatitis B virus X protein enhances the DNA binding potential and transcription efficacy of bZip transcription factors.
J. Biol. Chem.
272:20684-20690[Abstract/Free Full Text].
|
| 5.
|
Barone, M. V., and S. A. Courtneidge.
1995.
Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src.
Nature
378:509-512[CrossRef][Medline].
|
| 6.
|
Benn, J., and R. J. Schneider.
1994.
Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signalling cascade.
Proc. Natl. Acad. Sci. USA
91:10350-10354[Abstract/Free Full Text].
|
| 7.
|
Benn, J., and R. J. Schneider.
1995.
Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls.
Proc. Natl. Acad. Sci. USA
92:11215-11219[Abstract/Free Full Text].
|
| 8.
|
Benn, J.,
F. Su,
M. Doria, and R. J. Schneider.
1996.
Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases.
J. Virol.
70:4978-4985[Abstract/Free Full Text].
|
| 9.
|
Bergametti, F.,
S. Prigent,
B. Luber,
A. Benoit,
P. Tiollais,
A. Sarasin, and C. Transy.
1999.
The proapoptotic effect of hepatitis B virus HBx protein correlates with its transactivation activity in stably transfected cell lines.
Oncogene
18:2860-2871[CrossRef][Medline].
|
| 10.
|
Broome, M. A., and T. Hunter.
1996.
Requirement for c-Src catalytic activity and the SH3 domain in platelet-derived growth factor BB and epidermal growth factor mitogenic signaling.
J. Biol. Chem.
271:16798-16806[Abstract/Free Full Text].
|
| 11.
|
Burley, S., and R. Roeder.
1996.
Biochemistry and structural biology of transcription factor IID (TFIID).
Annu. Rev. Biochem.
65:769-799[CrossRef][Medline].
|
| 12.
|
Chen, H.-S.,
S. Kaneko,
R. Girones,
R. W. Anderson,
W. E. Hornbuckle,
B. C. Tennant,
P. J. Cote,
J. L. Gerin,
R. H. Purcell, and R. H. Miller.
1993.
The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks.
J. Virol.
67:1218-1226[Abstract/Free Full Text].
|
| 13.
|
Chen, I. S., and H. M. Temin.
1982.
Establishment of infection by spleen necrosis virus: inhibition in stationary cells and the role of secondary infection.
J. Virol.
41:183-191[Abstract/Free Full Text].
|
| 14.
|
Cheong, J.-H.,
M.-K. Yi,
Y. Lin, and S. Murakami.
1995.
Human RPB5, a subunit shared by eukaryotic nuclear polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation.
EMBO J.
14:143-150[Medline].
|
| 15.
|
Chirillo, P.,
M. Falco,
P. L. Puri,
M. Artini,
C. Balsano,
M. Levrero, and G. Natoli.
1996.
Hepatitis B virus pX activates NF- B-dependent transcription through a Raf-independent pathway.
J. Virol.
70:641-646[Abstract].
|
| 16.
|
Chirillo, P.,
S. Pagano,
G. Natoli,
P. L. Puri,
V. L. Burgio,
C. Balsano, and M. Levrero.
1997.
The hepatitis B virus X gene induces p53-mediated programmed cell death.
Proc. Natl. Acad. Sci. USA
94:8162-8167[Abstract/Free Full Text].
|
| 17.
|
Cong, Y.-S.,
Y.-L. Yao,
W.-M. Yang,
N. Kuzhandaivelu, and E. Seto.
1997.
The hepatitis B virus X-associated protein, XAP3, is a protein kinase C-binding protein.
J. Biol. Chem.
272:16482-16489[Abstract/Free Full Text].
|
| 18.
|
Cross, J. C.,
P. Wen, and W. J. Rutter.
1993.
Transactivation by hepatitis B virus X protein is promiscuous and dependent on mitogen activated cellular serine/threonine kinases.
Proc. Natl. Acad. Sci. USA
90:8078-8082[Abstract/Free Full Text].
|
| 19.
|
Damania, B., and J. Alwine.
1996.
TAF-like function of SV40 large T antigen.
Genes Dev.
10:1369-1381[Abstract/Free Full Text].
|
| 20.
|
Dandri, M.,
J. Petersen,
R. J. Stockert,
T. M. Harris, and C. E. Rogler.
1998.
Metabolic labeling of woodchuck hepatitis B virus X protein in naturally infected hepatocytes reveals a bimodal half-life and association with the nuclear framework.
J. Virol.
72:9359-9364[Abstract/Free Full Text].
|
| 21.
|
Dandri, M.,
P. Schirmacher, and C. E. Rogler.
1996.
Woodchuck hepatitis virus X protein is present in chronically infected woodchuck liver and woodchuck hepatocellular carcinomas which are permissive for viral replication.
J. Virol.
70:5246-5254[Abstract/Free Full Text].
|
| 22.
|
Denhardt, D. T.,
D. R. Edwards, and C. L. Parfett.
1986.
Gene expression during the mammalian cell cycle.
Biochim. Biophys. Acta
865:83-125[Medline].
|
| 23.
|
Doria, M.,
N. Klein,
R. Lucito, and R. J. Schneider.
1995.
Hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors.
EMBO J.
14:4747-4757[Medline].
|
| 24.
|
Dunphy, E. L.,
T. Johnson,
S. S. Auerbach, and E. H. Wang.
2000.
Requirement for TAFII250 acetyltransferase activity in cell cycle progression.
Mol. Cell. Biol.
20:1134-1139[Abstract/Free Full Text].
|
| 25.
|
Goulaouic, H.,
F. Subra,
J. F. Mouscadet,
S. Carteau, and C. Auclair.
1994.
Exogenous nucleosides promote the completion of MoMLV DNA synthesis in G0-arrested Balb c/3T3 fibroblasts.
Virology
200:87-97[CrossRef][Medline].
|
| 26.
|
Harel, J.,
E. Rassart, and P. Jolicoeur.
1981.
Cell cycle dependence of synthesis of unintegrated viral DNA in mouse cells newly infected with murine leukemia virus.
Virology
110:202-207[CrossRef][Medline].
|
| 27.
|
Haviv, I.,
Y. Matza, and Y. Shaul.
1998.
pX, the HBV-encoded coactivator, suppresses the phenotypes of TBP and TAFII250 mutants.
Genes Dev.
12:1217-1226[Abstract/Free Full Text].
|
| 28.
|
Haviv, I.,
M. Shamay,
G. Doitsch, and Y. Shaul.
1998.
Hepatitis B virus pX targets TFIIB in transcription coactivation.
Mol. Cell. Biol.
18:1562-1569[Abstract/Free Full Text].
|
| 29.
|
Haviv, I.,
D. Vaizel, and Y. Shaul.
1996.
pX, the HBV-encoded coactivator, interacts with components of the transcription machinery and stimulates transcription in a TAF-independent manner.
EMBO J.
15:3413-3420[Medline].
|
| 30.
|
Haviv, I.,
D. Vaizel, and Y. Shaul.
1995.
The X protein of hepatitis B virus coactivates potent activation domains.
Mol. Cell. Biol.
15:1079-1085[Abstract].
|
| 31.
|
Hayashida, T.,
T. Sekiguchi,
E. Noguchi,
H. Sunamoto,
T. Ohba, and T. Nishimoto.
1994.
The CCG1/TAFII250 gene is mutated in thermosensitive G1 mutants of the BHK21 cell line derived from golden hamster.
Gene
141:267-270[CrossRef][Medline].
|
| 32.
|
Henkler, F.,
A. R. Lopes,
M. Jones, and R. Koshy.
1998.
Erk-independent partial activation of AP-1 sites by the hepatitis B virus HBx protein.
J. Gen. Virol.
79:2737-2742[Abstract].
|
| 33.
|
Hermann, C. P.,
S. Krais, and M. Montenarch.
1991.
Association of casein kinase II with immunopurified p53.
Oncogene
6:877-886[Medline].
|
| 34.
|
Ignatius, M. J.,
C. R. Chandler, and E. M. Shooter.
1985.
Nerve growth factor-treated neurite bearing PC12 cells continue to synthesize DNA.
J. Neurosci.
5:343-351[Abstract].
|
| 35.
|
Jacob, J. R.,
M. A. Ascenzi,
C. A. Roneker,
I. A. Toshkov,
P. J. Cote,
J. L. Gerin, and B. C. Tennant.
1997.
Hepatic expression of the woodchuck hepatitis virus X-antigen during acute and chronic infection and detection of a woodchuck hepatitis virus X-antigen antibody response.
Hepatology
26:1607-1615[CrossRef][Medline].
|
| 36.
|
Jacobson, R. H.,
A. G. Ladurner,
D. S. King, and R. Tjian.
2000.
Structure and function of a human TAFII250 double bromodomain module.
Science
288:1422-1425[Abstract/Free Full Text].
|
| 37.
|
Johnson, D.,
M. C. Frame, and J. A. Wyke.
1998.
Expression of the v-Src oncoprotein in fibroblasts disrupts normal regulation of the CDK inhibitor p27 and inhibits quiescence.
Oncogene
16:2017-2028[CrossRef][Medline].
|
| 38.
|
Kekule, A. S.,
U. Lauer,
L. Weiss,
B. Luber, and P. H. Hofschneider.
1993.
Hepatitis B virus transactivator HBx uses a tumor promoter signalling pathway.
Nature
361:742-745[CrossRef][Medline].
|
| 39.
|
Kim, H.,
H. Lee, and Y. Yun.
1998.
X-gene product of hepatitis B virus induces apoptosis in liver cells.
J. Biol. Chem.
273:381-385[Abstract/Free Full Text].
|
| 40.
|
Klein, N.,
M. Bouchard,
L.-H. Wang,
C. Kobarg, and R. J. Schneider.
1999.
Src kinases involved in hepatitis B virus replication.
EMBO J.
18:5019-5027[CrossRef][Medline].
|
| 41.
|
Klein, N. P., and R. J. Schneider.
1997.
Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras.
Mol. Cell. Biol.
17:6427-6436[Abstract].
|
| 42.
|
Koike, K.,
K. Moriya,
H. Yotsuyanagi,
S. Iino, and K. Kurokawa.
1994.
Induction of cell cycle progression by hepatitis B virus HBx gene expression in quiescent mouse fibroblasts.
J. Clin. Investig.
94:44-49.
|
| 43.
|
Kwee, L.,
R. Lucito,
B. Aufiero, and R. J. Schneider.
1992.
Alternate translation initiation on hepatitis B virus X mRNA produces multiple polypeptides that differentially transactivate class II and III promoters.
J. Virol.
66:4382-4389[Abstract/Free Full Text].
|
| 44.
|
Lee, R. J.,
C. Albanese,
R. J. Stenger,
G. Watanabe,
G. Inghirami,
G. K. Haines III,
M. Webster,
W. J. Muller,
J. S. Brugge,
R. J. Davis, and R. G. Pestell.
1999.
pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells.
J. Biol. Chem.
274:7341-7350[Abstract/Free Full Text].
|
| 45.
|
Levrero, M.,
C. Balsano,
G. Natoli,
M. L. Avantaggiati, and E. Elfassi.
1990.
Hepatitis B virus X protein transactivates the long terminal repeats of human immunodeficiency virus types 1 and 2.
J. Virol.
64:3082-3086[Abstract/Free Full Text].
|
| 46.
|
Lin, Y.,
T. Nomura,
J. Cheong,
D. Dorjsuren,
K. Iida, and S. Murakami.
1997.
Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and RNA polymerase II subunit 5.
J. Biol. Chem.
272:7132-7139[Abstract/Free Full Text].
|
| 47.
|
Liu, H.,
C. Gibson,
R. Hirschhorn,
S. Rittling,
R. Baserga, and W. Mercer.
1985.
Expression of thymidine kinase and dihydrofolate reductase genes in mammalian ts mutants of the cell cycle.
J. Biol. Chem.
260:3269-3274[Abstract/Free Full Text].
|
| 48.
|
Lucito, R., and R. J. Schneider.
1992.
Hepatitis B virus X protein activates transcription factor NF- B without a requirement for protein kinase C.
J. Virol.
66:983-991[Abstract/Free Full Text].
|
| 49.
|
Lukac, D.,
N. Harel,
N. Tanese, and J. Alwine.
1997.
TAF-like functions of human cytomegalovirus immediate-early proteins.
J. Virol.
71:7227-7239[Abstract].
|
| 50.
|
Lukac, D. M., and J. C. Alwine.
1999.
Effects of human cytomegalovirus major immediate-early proteins in controlling the cell cycle and inhibiting apoptosis: studies with ts13 cells.
J. Virol.
73:2825-2831[Abstract/Free Full Text].
|
| 51.
|
Maguire, H. F.,
J. P. Hoeffler, and A. Siddiqui.
1991.
HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions.
Science
252:842-844[Abstract/Free Full Text].
|
| 52.
|
Mahe, Y.,
N. Mukaida,
K. Kuno,
M. Akiyama,
N. Ikeda,
K. Matshushima, and S. Murakami.
1991.
Hepatitis B virus X protein transactivates human interleukin-8 gene through acting on nuclear factor B and CCAAT/enhancer-binding protein-like cis elements.
J. Biol. Chem.
266:13759-13763[Abstract/Free Full Text].
|
| 53.
|
Mou, S., and D. Linnekin.
1999.
Lyn is activated during late G1 of stem-cell-factor-induced cell cycle progression in haemopoietic cells.
Biochem. J.
342:163-170.
|
| 54.
|
Murakami, S.,
J.-H. Cheong,
S. Ohno,
K. Matsushima, and S. Kaneko.
1994.
Transactivation of human hepatitis B virus X protein, HBx, operates through a mechanism distinct from protein kinase C and okadaic acid activation pathways.
Virology
199:243-246[CrossRef][Medline].
|
| 55.
|
Natoli, G.,
M. L. Avantaggiati,
P. Chirillo,
P. L. Puri,
A. Ianni,
C. Balsano, and M. Levrero.
1994.
Ras- and raf-dependent activation of c-jun transcriptional activity by the hepatitis B virus transactivator pX.
Oncogene
9:2837-2843[Medline].
|
| 56.
|
Nebigil, C. G.,
J. M. Launay,
P. Hickel,
C. Tournois, and L. Maroteaux.
2000.
5-Hydroxytryptamine 2B receptor regulates cell-cycle progression: cross-talk with tyrosine kinase pathways.
Proc. Natl. Acad. Sci. USA
97:2591-2596[Abstract/Free Full Text].
|
| 57.
|
Ozer, A.,
V. I. Khaoustov,
M. Mearns,
D. E. Lewis,
R. M. Genta,
G. J. Darlington, and B. Yoffee.
1996.
Effect of hepatocyte proliferation and cellular DNA synthesis on hepatitis B virus replication.
Gastroenterology
110:1519-1528[CrossRef][Medline].
|
| 58.
|
Pennisi, E.
2000.
Matching the transcription machinery to the right DNA.
Science
288:1372-1373[Free Full Text].
|
| 59.
|
Perini, G.,
E. Oetjen, and M. R. Green.
1999.
The hepatitis B pX protein promotes dimerization and DNA binding of cellular basic region/leucine zipper proteins by targeting the conserved basic region.
J. Biol. Chem.
274:13970-13977[Abstract/Free Full Text].
|
| 60.
|
Qadri, I.,
J. W. Conaway,
R. C. Conaway,
J. Schaack, and A. Siddiqui.
1996.
Hepatitis B virus transactivator protein, HBx, associates with the components of TFIIH and stimulates the DNA helicase activity of TFIIH.
Proc. Natl. Acad. Sci. USA
93:10578-10583[Abstract/Free Full Text].
|
| 61.
|
Qadri, I.,
H. F. Maguire, and A. Siddiqui.
1995.
Hepatitis B virus transactivator protein X interacts with the TATA-binding protein.
Proc. Natl. Acad. Sci. USA
92:1003-1007[Abstract/Free Full Text].
|
| 62.
|
Rabinovitch, P. S.
1994.
DNA content histogram and cell-cycle analysis.
Methods Cell Biol.
41:263-296[Medline].
|
| 63.
|
Rahmani, Z.,
K. W. Huh,
R. Lasher, and A. Siddiqui.
2000.
Hepatitis B virus X protein colocalizes to mitochondria with a human voltage-dependent anion channel, HVDAC3, and alters its transmembrane potential.
J. Virol.
74:2840-2846[Abstract/Free Full Text].
|
| 64.
|
Roche, S.,
M. Koegl,
M. V. Barone,
M. F. Roussel, and S. A. Courtneidge.
1995.
DNA synthesis induced by some but not all growth factors requires Src family protein tyrosine kinases.
Mol. Cell. Biol.
15:1102-1109[Abstract].
|
| 65.
|
Roussel, M. F.
1997.
Key effectors of signal transduction and G1 progression.
Adv. Cancer Res.
74:1-24.
|
| 66.
|
Schuster, R.,
W. H. Gerlich, and S. Schaefer.
2000.
Induction of apoptosis by the transactivating domains of the hepatitis B virus X gene leads to suppression of oncogenic transformation of primary rat embryo fibroblasts.
Oncogene
19:1173-1180[CrossRef][Medline].
|
| 67.
|
Sekiguchi, T.,
T. Makashima,
T. Hayashida,
A. Kuraoka,
S. Hashimoto,
N. Tsuchida,
Y. Shibata,
T. Hunter, and T. Nishimoto.
1995.
Apoptosis is induced in BHK cells by the tsBN462/13 mutation in CCG1/TAFII250 subunit of the TFIID basal transcription factor.
Exp. Cell Res.
218:490-498[CrossRef][Medline].
|
| 68.
|
Seto, E.,
P. J. Mitchell, and T. S. B. Yen.
1990.
Transactivation by the hepatitis B virus X protein depends on AP-2 and other transcription factors.
Nature
344:72-74[Medline].
|
| 69.
|
Shimizu, M.,
Y. Nomura,
H. Suzuki,
E. Ichikawa,
A. Takeuchi,
M. Suzuki,
T. Nakamura,
T. Nakajima, and K. Oda.
1998.
Activation of the rat cyclin A promoter by ATF2 and Jun family members and its suppression by ATF4.
Exp. Cell Res.
239:93-103[CrossRef][Medline].
|
| 70.
|
Shintani, Y.,
H. Yotsuyanagi,
K. Moriya,
H. Fujie,
T. Tsutsumi,
Y. Kanegae,
S. Kimura,
I. Saito, and K. Koike.
1999.
Induction of apoptosis after switch-on of the hepatitis B virus X gene mediated by the Cre/loxP recombination system.
J. Gen. Virol.
80:3257-3265[Abstract/Free Full Text].
|
| 71.
|
Sirma, H.,
C. Giannini,
K. Poussin,
P. Paterlini,
D. Kremsdorf, and C. Brechot.
1999.
Hepatitis B virus X mutants present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx.
Oncogene
18:4848-4859[CrossRef][Medline].
|
| 72.
|
Sirma, H.,
R. Weil,
O. Rosmorduc,
S. Urban,
A. Israel,
D. Kremsdorf, and C. Brechot.
1998.
Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome.
Oncogene
16:2051-2063[CrossRef][Medline].
|
| 73.
|
Su, F., and R. J. Schneider.
1996.
Hepatitis B virus HBx protein activates transcription factor NF- B by acting on multiple cytoplasmic inhibitors of rel-related proteins.
J. Virol.
70:4558-4566[Abstract].
|
| 74.
|
Su, F., and R. J. Schneider.
1997.
Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by TNF .
Proc. Natl. Acad. Sci. USA
94:8744-8749[Abstract/Free Full Text].
|
| 75.
|
Suzuki-Yagawa, Y.,
M. Guermah, and R. G. Roeder.
1997.
The ts13 mutation in the TAFII250 subunit (CCG1) of TFIID directly affects transcription of D-type cyclin genes in cells arrested in G1 at the nonpermissive temperature.
Mol. Cell. Biol.
17:3284-3294[Abstract].
|
| 76.
|
Talavera, A., and C. Basilico.
1977.
Temperature sensitive mutants of BHK cells affected in cell cycle progression.
J. Cell. Physiol.
92:425-436[CrossRef][Medline].
|
| 77.
|
Tarn, C.,
M. L. Bilodeau,
R. L. Hullinger, and O. M. Andrisani.
1999.
Differential immediate early gene expression in conditional hepatitis B virus pX-transforming versus nontransforming hepatocyte cell lines.
J. Biol. Chem.
274:2327-2336[Abstract/Free Full Text].
|
| 78.
|
Terradillos, O.,
O. Billet,
C.-A. Renard,
R. Levy,
T. Molina,
P. Briand, and M. A. Buendia.
1997.
The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice.
Oncogene
14:395-404[CrossRef][Medline].
|
| 79.
|
Terradillos, O.,
T. Pollicino,
H. Lecoeur,
M. Tripodi,
M. L. Gougeon,
P. Tiollais, and M. A. Buendia.
1998.
p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro.
Oncogene
17:2115-2123[CrossRef][Medline].
|
| 80.
|
Thomas, S. M., and J. S. Brugge.
1997.
Cellular functions regulated by Src family kinases.
Annu. Rev. Cell Dev. Biol.
13:513-609[CrossRef][Medline].
|
| 81.
|
Twu, J.-S.,
M.-Y. Lai,
D.-S. Chen, and W. S. Robinson.
1993.
Activation of protooncogene c-jun by the X protein of hepatitis B virus.
Virology
192:346-350[CrossRef][Medline].
|
| 82.
|
Twu, J.-S., and W. S. Robinson.
1989.
Hepatitis B virus X gene can transactivate heterologous viral sequences.
Proc. Natl. Acad. Sci. USA
86:2046-2050[Abstract/Free Full Text].
|
| 83.
|
Unger, T., and Y. Shaul.
1990.
The X protein of the hepatitis B virus acts as a transcription factor when targeted to its responsive element.
EMBO J.
9:1889-1895[Medline].
|
| 84.
|
Wang, E., and R. Tjian.
1994.
Promoter-selective transcriptional defect in cell cycle mutant ts13 rescued by hTAFII250.
Science
263:811-814[Abstract/Free Full Text].
|
| 85.
|
Wang, E.,
S. Zou, and R. Tjian.
1997.
TAFII250-dependent transcription of cyclin A is directed by ATF activator proteins.
Genes Dev.
11:2658-2669[Abstract/Free Full Text].
|
| 86.
|
Wang, H.-D.,
A. Trivedi, and D. L. Johnson.
1997.
Hepatitis B virus X protein induces RNA polymerase III-dependent gene transcription and increases cellular TATA-binding protein by activating the Ras signaling pathway.
Mol. Cell. Biol.
17:6838-6846[Abstract].
|
| 87.
|
Wang, H.-D.,
C.-H. Yuh,
C. V. Dang, and D. L. Johnson.
1995.
The hepatitis B virus X protein increases the cellular level of TATA-binding protein which mediates transactivation of RNA polymerase III genes.
Mol. Cell. Biol.
15:6720-6728[Abstract].
|
| 88.
|
Wang, H. D.,
A. Trivedi, and D. L. Johnson.
1998.
Regulation of RNA polymerase I-dependent promoters by the hepatitis B virus X protein via activated Ras and TATA-binding protein.
Mol. Cell. Biol.
18:7086-7094[Abstract/Free Full Text].
|
| 89.
|
Weinzierl, R.,
B. Dynlacht, and R. Tjian.
1993.
Largest subunit of Drosophila transcription factor IID directs assembly of a complex containing TBP and a coactivator.
Nature
362:511-517[CrossRef][Medline].
|
| 90.
|
Williams, J. S., and O. M. Andrisani.
1995.
The hepatitis B virus X protein targets the basic region-leucine zipper domain of CREB.
Proc. Natl. Acad. Sci. USA
92:3819-3823[Abstract/Free Full Text].
|
| 91.
|
Xie, W.,
B. S. Fletcher,
R. D. Andersen, and H. R. Herschman.
1994.
v-src induction of the TIS10/PGS2 prostaglandin synthase gene is mediated by an ATF/CRE transcription response element.
Mol. Cell. Biol.
14:6531-6539[Abstract/Free Full Text].
|
| 92.
|
Yen, T. S. B.
1996.
Hepadnaviral X protein: review of recent progress.
J. Biomed. Sci.
3:20-30[CrossRef][Medline].
|
| 93.
|
Zack, J. A.,
S. J. Arrigo,
S. R. Weitsman,
A. S. Go,
A. Haislip, and I. S. Chen.
1990.
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.
Cell
61:213-222[CrossRef][Medline].
|
| 94.
|
Zack, J. A.,
A. M. Haislip,
P. Krogstad, and I. S. Chen.
1992.
Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle.
J. Virol.
66:1717-1725[Abstract/Free Full Text].
|
| 95.
|
Zoulim, F.,
J. Saputelli, and C. Seeger.
1994.
Woodchuck hepatitis virus X protein is required for viral infection in vivo.
J. Virol.
68:2026-2030[Abstract/Free Full Text].
|
Journal of Virology, May 2001, p. 4247-4257, Vol. 75, No. 9
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.9.4247-4257.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
McClain, S. L., Clippinger, A. J., Lizzano, R., Bouchard, M. J.
(2007). Hepatitis B Virus Replication Is Associated with an HBx-Dependent Mitochondrion-Regulated Increase in Cytosolic Calcium Levels. J. Virol.
81: 12061-12065
[Abstract]
[Full Text]
-
Puro, R., Schneider, R. J.
(2007). Tumor Necrosis Factor Activates a Conserved Innate Antiviral Response to Hepatitis B Virus That Destabilizes Nucleocapsids and Reduces Nuclear Viral DNA. J. Virol.
81: 7351-7362
[Abstract]
[Full Text]
-
Cougot, D., Wu, Y., Cairo, S., Caramel, J., Renard, C.-A., Levy, L., Buendia, M. A., Neuveut, C.
(2007). The Hepatitis B Virus X Protein Functionally Interacts with CREB-binding Protein/p300 in the Regulation of CREB-mediated Transcription. J. Biol. Chem.
282: 4277-4287
[Abstract]
[Full Text]
-
Li, H., Chi, C.-Y., Lee, S., Andrisani, O. M.
(2006). The Mitogenic Function of Hepatitis B Virus X Protein Resides within Amino Acids 51 to 140 and Is Modulated by N- and C-Terminal Regulatory Regions. J. Virol.
80: 10554-10564
[Abstract]
[Full Text]
-
Park, N H, Song, I H, Chung, Y-H
(2006). Chronic hepatitis B in hepatocarcinogenesis.. Postgrad. Med. J.
82: 507-515
[Abstract]
[Full Text]
-
Bouchard, M. J., Wang, L., Schneider, R. J.
(2006). Activation of Focal Adhesion Kinase by Hepatitis B Virus HBx Protein: Multiple Functions in Viral Replication. J. Virol.
80: 4406-4414
[Abstract]
[Full Text]
-
Guo, H., Mason, W. S., Aldrich, C. E., Saputelli, J. R., Miller, D. S., Jilbert, A. R., Newbold, J. E.
(2005). Identification and Characterization of Avihepadnaviruses Isolated from Exotic Anseriformes Maintained in Captivity. J. Virol.
79: 2729-2742
[Abstract]
[Full Text]
-
Chou, Y.-C., Jeng, K.-S., Chen, M.-L., Liu, H.-H., Liu, T.-L., Chen, Y.-L., Liu, Y.-C., Hu, C.-p., Chang, C.
(2005). Evaluation of Transcriptional Efficiency of Hepatitis B Virus Covalently Closed Circular DNA by Reverse Transcription-PCR Combined with the Restriction Enzyme Digestion Method. J. Virol.
79: 1813-1823
[Abstract]
[Full Text]
-
Bouchard, M. J., Schneider, R. J.
(2004). The Enigmatic X Gene of Hepatitis B Virus. J. Virol.
78: 12725-12734
[Full Text]
-
Kwun, H. J., Jang, K. L.
(2004). Natural variants of hepatitis B virus X protein have differential effects on the expression of cyclin-dependent kinase inhibitor p21 gene. Nucleic Acids Res
32: 2202-2213
[Abstract]
[Full Text]
-
Shih, W.-L., Kuo, M.-L., Chuang, S.-E., Cheng, A.-L., Doong, S.-L.
(2003). Hepatitis B Virus X Protein Activates a Survival Signaling by Linking Src to Phosphatidylinositol 3-Kinase. J. Biol. Chem.
278: 31807-31813
[Abstract]
[Full Text]
-
Biermer, M., Puro, R., Schneider, R. J.
(2003). Tumor Necrosis Factor Alpha Inhibition of Hepatitis B Virus Replication Involves Disruption of Capsid Integrity through Activation of NF-{kappa}B. J. Virol.
77: 4033-4042
[Abstract]
[Full Text]
-
Tarn, C., Zou, L., Hullinger, R. L., Andrisani, O. M.
(2002). Hepatitis B Virus X Protein Activates the p38 Mitogen-Activated Protein Kinase Pathway in Dedifferentiated Hepatocytes. J. Virol.
76: 9763-9772
[Abstract]
[Full Text]
-
Lee, S., Tarn, C., Wang, W.-H., Chen, S., Hullinger, R. L., Andrisani, O. M.
(2002). Hepatitis B Virus X Protein Differentially Regulates Cell Cycle Progression in X-transforming Versus Nontransforming Hepatocyte (AML12) Cell Lines. J. Biol. Chem.
277: 8730-8740
[Abstract]
[Full Text]